It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
Static [18F]-F-DOPA PET images are currently used for identifying patients with glioma recurrence/progression after treatment, although the additional diagnostic value of dynamic parameters remains unknown in this setting. The aim of this study was to evaluate the performances of static and dynamic [18F]-F-DOPA PET parameters for detecting patients with glioma recurrence/progression as well as assess further relationships with patient outcome.
Methods
Fifty-one consecutive patients who underwent an [18F]-F-DOPA PET for a suspected glioma recurrence/progression at post-resection MRI, were retrospectively included. Static parameters, including mean and maximum tumor-to-normal-brain (TBR) ratios, tumor-to-striatum (TSR) ratios, and metabolic tumor volume (MTV), as well as dynamic parameters with time-to-peak (TTP) values and curve slope, were tested for predicting the following: (1) glioma recurrence/progression at 6 months after the PET exam and (2) survival on longer follow-up.
Results
All static parameters were significant predictors of glioma recurrence/progression (accuracy ≥ 94%) with all parameters also associated with mean progression-free survival (PFS) in the overall population (all p < 0.001, 29.7 vs. 0.4 months for TBRmax, TSRmax, and MTV). The curve slope was the sole dynamic PET predictor of glioma recurrence/progression (accuracy = 76.5%) and was also associated with mean PFS (p < 0.001, 18.0 vs. 0.4 months). However, no additional information was provided relative to static parameters in multivariate analysis.
Conclusion
Although patients with glioma recurrence/progression can be detected by both static and dynamic [18F]-F-DOPA PET parameters, most of this diagnostic information can be achieved by conventional static parameters.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Université de Lorraine, CHRU-Nancy, Department of Nuclear Medicine & Nancyclotep Imaging platform, Nancy, France; Université de Lorraine, IADI, INSERM, UMR 1254, Nancy, France (GRID:grid.29172.3f) (ISNI:0000 0001 2194 6418)
2 Université de Lorraine, CHRU-Nancy, Department of Nuclear Medicine & Nancyclotep Imaging platform, Nancy, France (GRID:grid.29172.3f)
3 Université de Lorraine, CHRU-Nancy, Department of Nuclear Medicine & Nancyclotep Imaging platform, Nancy, France (GRID:grid.29172.3f); Université de Lorraine, INSERM, U1116, Nancy, France (GRID:grid.29172.3f) (ISNI:0000 0001 2194 6418)
4 Université de Lorraine, CHRU-Nancy, Department of Pathology, Nancy, France (GRID:grid.29172.3f); Université de Lorraine, INSERM U1256, Nancy, France (GRID:grid.29172.3f) (ISNI:0000 0001 2194 6418)
5 Université de Lorraine, CHRU-Nancy, Department of Neurosurgery, Nancy, France (GRID:grid.29172.3f); Université de Lorraine, Centre de Recherche en Automatique de Nancy CRAN, CNRS UMR 7039, Nancy, France (GRID:grid.29172.3f) (ISNI:0000 0001 2194 6418)
6 Université de Lorraine, Centre de Recherche en Automatique de Nancy CRAN, CNRS UMR 7039, Nancy, France (GRID:grid.29172.3f) (ISNI:0000 0001 2194 6418); Université de Lorraine, CHRU-Nancy, Department of Neuro-oncology, Nancy, France (GRID:grid.29172.3f)
7 Université de Lorraine, INSERM, U1116, Nancy, France (GRID:grid.29172.3f) (ISNI:0000 0001 2194 6418)
8 Université de Lorraine, CHRU-Nancy, Department of Nuclear Medicine & Nancyclotep Imaging platform, Nancy, France (GRID:grid.29172.3f); Université de Lorraine, IADI, INSERM, UMR 1254, Nancy, France (GRID:grid.29172.3f) (ISNI:0000 0001 2194 6418)